Biomarkers predicting treatment outcome in depression: What is clinically significant?

Pharmacogenomics

Volumn 13, Issue 2, 2012, Pages 233-240

  Uher, Rudolf ^a,b   Tansey, Katherine E ^a   Malki, Karim ^a   Perlis, Roy H ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b DALHOUSIE UNIVERSITY   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

antidepressant medication; biomarkers; clinical significance; major depressive disorder; number needed to assess

Indexed keywords

BIOLOGICAL MARKER;

ALGORITHM; ALLELE; ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; EFFECT SIZE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HUMAN; MATHEMATICAL MODEL; OUTCOMES RESEARCH; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM;

ANTIDEPRESSIVE AGENTS; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DEPRESSION; GENOTYPE; HUMANS; REFERENCE STANDARDS; TREATMENT OUTCOME;

EID: 84855916364     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.161     Document Type: Article

References (31)

1. Perlis RH. Translating biomarkers to clinical practice. Mol. Psychiatry 16(11), 1076-1087 (2011).
2. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J. Consult. Clin. Psychol. 59(1), 12-19 (1991).
3. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 5(2), e45 (2008).
4. Kraemer HC. Reporting the size of effects in research studies to facilitate assessment of practical or clinical significance. Psychoneuroendocrinology 17(6), 527-536 (1992). (Pubitemid 23043117)
5. National Institute for Clinical Excellence. The Treatment and Management of Depression in Adults. NICE, Department of Health, London, UK (2009).
6. National Institute for Clinical Excellence. Depression: Management of Depression in Primary and Secondary Care. NICE, Department of Health, London, UK (2004).
7. Fountoulakis KN, Moller HJ. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int. J. Neuropsychopharmacol. 14(3), 405-412 (2011).
8. Fournier JC, DeRubeis RJ, Hollon SD et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303(1), 47-53 (2010).
9. Muller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J. Affect. Disord. 77(3), 255-260 (2003). (Pubitemid 37377919)
10. Carmody TJ, Rush AJ, Bernstein I et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur. Neuropsychopharmacol. 16(8), 601-611 (2006). (Pubitemid 44716667)
11. Uher R, Farmer A, Maier W et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol. Med. 38(2), 289-300 (2008). (Pubitemid 351156595)
12. Rush AJ, Fava M, Wisniewski SR et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin. Trials 25(1), 119-142 (2004). (Pubitemid 38230109)
13. Uher R, Maier W, Hauser J et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br. J. Psychiatry 194(3), 252-259 (2009).
14. Ellis PD. The Essential Guide to Effect Sizes. Ellis PD (Ed.). Cambridge University Press, Cambridge, UK (2010).
15. Frank E, Prien RF, Jarrett RB et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch. Gen. Psychiatry 48(9), 851-855 (1991).
16. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol. Psychiatry 59(11), 990-996 (2006). (Pubitemid 43849650)
17. Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 34(10), 2227-2236 (2009).
18. Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am. J. Psychiatry 167(12), 1445-1455 (2010).
19. Kunz M. On responder analyses when a continuous variable is dichotomized and measurement error is present. Biom. J. 53(1), 137-155 (2011).
20. Deyi BA, Kosinski AS, Snapinn SM. Power considerations when a continuous outcome variable is dichotomized. J. Biopharm. Stat. 8(2), 337-352 (1998). (Pubitemid 28239876)
21. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 332(7549), 1080 (2006). (Pubitemid 44365491)
22. Streiner DL. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can. J. Psychiatry 47(3), 262-266 (2002). (Pubitemid 34614684)
23. Ising M, Lucae S, Binder EB et al. A genome wide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 66(9), 966-975 (2009).
24. Garriock HA, Kraft JB, Shyn SI et al. A genome wide association study of citalopram response in major depressive disorder. Biol. Psychiatry 67(2), 133-138 (2010).
25. Uher R, Perroud N, Ng MY et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 167(5), 555-564 (2010).
26. Purcell SM, Wray NR, Stone JL et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460(7256), 748-752 (2009).
27. Evans DM, Visscher PM, Wray NR. Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. Hum. Mol. Genet. 18(18), 3525-3531 (2009).
28. Uher R. Genes, environment, and individual differences in responding to treatment for depression. Harv. Rev. Psychiatry 19(3), 109-124 (2011).
29. Joyce PR, McKenzie JM, Carter JD et al. Temperament, character and personality disorders as predictors of response to interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br. J. Psychiatry 190, 503-508 (2007). (Pubitemid 46868834)
30. Uher R, Perlis RH, Henigsberg N et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol. Med. 20, 1-14 (2011).
31. Uher R, Dernovsek MZ, Mors O et al. Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. J. Affect. Disord. 132(1-2), 112-120 (2011).